Thus, PD-L1 expression modulation in the plasma membrane of cancer cells by therapeutic agents targeting ezrin and/or radixin may represent a novel treatment strategy to boost the efficacy of PD-1/PD-L1 blockade therapies in CRC. This evidence concerns the gene PDCD1 and cancer.